Beyond AAV Titer: Why Batch Consistency and Empty Capsid Control Are Central to CMC Success

Introduction

As more gene therapy programs advance toward investigational new drug applications, Chemistry, Manufacturing, and Controls expectations for adeno-associated virus, or AAV, products have become increasingly rigorous. In early discovery, many teams focus primarily on whether the vector genome titer is high enough. A clean qPCR or ddPCR result reported as vg/mL can create confidence that a program is ready to move forward.

However, regulatory review of an AAV product rarely stops at titer. Reviewers are more likely to ask whether the sponsor understands and controls the product’s critical quality attributes. Two questions are especially important:

• What is the empty-to-full capsid ratio?
• How consistent are the results across manufacturing batches?

These questions can determine whether an AAV program is ready for IND-enabling development or whether additional process development, analytical characterization, and comparability work are needed.

A high vector genome titer may be an entry point, but it is not sufficient evidence of product quality. For AAV CMC, batch-to-batch consistency and capsid quality are often more important than a single attractive vg/mL number.

The Limitations of AAV Titer

When people refer to AAV titer, they usually mean vector genome titer, which is measured as vector genomes per milliliter using qPCR or ddPCR. This value represents the number of detectable target genome copies in the sample. It is an essential measurement, but it does not tell the full story.

AAV manufacturing generates a heterogeneous population of particles, including:

• Full capsids, which contain the intended therapeutic genome
• Empty capsids, which contain the protein shell but no vector genome
• Partially packaged capsids, which contain incomplete genomes or fragments of nucleic acid
• Aberrantly packaged capsids, which may contain unintended or non-target nucleic acid species

qPCR and ddPCR quantify specific vector genome sequences. They do not directly measure total capsid number, empty capsids, capsid protein content, or whether the packaged genome is intact and functional. As a result, two AAV lots with the same vg/mL value may differ substantially in potency, safety profile, impurity burden, and clinical suitability.

In practical terms, vector genome titer does not equal effective dose. A high titer may still be associated with a high proportion of non-functional or incompletely characterized particles.

Why Empty Capsid Ratio Matters

Empty capsids are not therapeutically active because they do not carry the intended genetic payload. However, they are not biologically irrelevant. Empty capsids may still interact with cells, bind receptors, contribute to total capsid burden, and influence immune responses.

Depending on the production system, plasmid ratio, harvest conditions, and purification strategy, empty and partially filled capsids can represent a substantial fraction of the final AAV preparation. Therefore, empty capsid ratio is increasingly viewed as a critical quality attribute rather than a secondary analytical detail.

For systemic AAV products, the issue becomes even more important because patients may receive large total capsid loads. A formulation with a high proportion of empty capsids may expose patients to more capsid protein without a corresponding increase in therapeutic genome delivery.

Analytical Methods for Empty Capsid Characterization

The reliability of empty capsid data depends heavily on the analytical method used. No single method is perfect, and the appropriate strategy depends on development stage, sample availability, regulatory expectations, and product-specific risk.

Analytical Ultracentrifugation

Analytical ultracentrifugation, or AUC, separates particles based on sedimentation behavior. It can distinguish empty, full, and partially filled capsid populations and is widely regarded as a strong reference method for AAV capsid characterization.

AUC provides quantitative and relatively high-confidence information, but it is time-consuming, low-throughput, and requires specialized expertise and instrumentation. It also generally requires more sample than some emerging methods. Despite these limitations, AUC remains one of the most important tools for GMP release testing, comparability assessment, and regulatory submission packages.

SEC-MALS

Size-exclusion chromatography coupled with multi-angle light scattering, or SEC-MALS, separates AAV particles from other species and measures molecular mass and size-related attributes. It can provide useful information on capsid content, aggregation, purity, and particle size distribution.

SEC-MALS is faster and more operationally convenient than AUC, making it valuable for process development and potentially for release testing after appropriate method qualification or validation. However, its resolving power for complex full, empty, and partial capsid populations may be lower than that of AUC.

Microfluidic Resistive Pulse Sensing

Microfluidic resistive pulse sensing platforms, such as Samux-MP, characterize particles as they pass through nanoscale pores. The signal generated during passage can provide information related to particle size and capsid filling status.

These methods can be rapid and require small sample volumes. They are useful for process development and advanced characterization, but broader regulatory acceptance depends on product-specific validation, method robustness, and demonstrated correlation with established orthogonal methods.

Transmission Electron Microscopy

Transmission electron microscopy, or TEM, allows direct visualization of AAV particles and can provide intuitive evidence of particle morphology and apparent capsid filling.

TEM is useful in early process development, but it has limitations. The number of particles counted is often limited, interpretation can be operator-dependent, and the method is not ideal for precise quantitative release testing. TEM should generally be used as supportive or orthogonal evidence rather than as the sole basis for empty capsid control.

A260/A280 Ratio

The A260/A280 absorbance ratio estimates nucleic acid and protein content and can provide a rapid, low-cost approximation. However, it is strongly affected by protein impurities, nucleic acid fragments, excipients, buffer composition, and pH.

For AAV products, A260/A280 alone is not sufficient for regulatory-grade empty capsid characterization. It may be useful for internal process monitoring, but it should not be presented as a comprehensive quality assessment for IND-enabling or GMP-stage development.

Regulatory Perspective on Empty Capsids

Regulatory agencies expect sponsors to understand, characterize, and control product-related and process-related impurities for gene therapy products. For AAV vectors, this includes characterization of capsid populations, vector genome integrity, potency, residual host cell DNA, residual plasmid DNA, host cell proteins, aggregates, and other product- or process-related impurities.

There is currently no universal regulatory release limit for empty capsids that applies to all AAV products. Instead, the acceptable level should be justified based on the product, route of administration, dose, indication, patient population, nonclinical safety package, and clinical risk-benefit profile.

A proposed industry draft from Dark Horse Consulting suggested a maximum release criterion for empty AAV capsids, but this proposal has not been formally adopted by FDA as a binding regulatory requirement. Therefore, it is more accurate to state that empty capsid control is a regulatory expectation, while the specific acceptance criterion must be product-specific and scientifically justified.

Batch-to-Batch Consistency Is a Core CMC Requirement

Titer and empty capsid ratio are important, but they are not sufficient unless they are reproducible. Batch-to-batch consistency demonstrates that the manufacturing process is controlled and capable of producing material with comparable quality attributes.

For AAV products, batch consistency should generally include evaluation of:

• Vector genome titer
• Total capsid concentration
• Empty, partial, and full capsid distribution
• Genome integrity
• Potency or biological activity
• Purity and impurity profile
• Residual host cell DNA and host cell protein
• Residual plasmid DNA
• Aggregation
• Sterility, endotoxin, and bioburden where applicable
• Stability-indicating attributes

A single high-performing batch may not be persuasive if subsequent batches show major variability. From a CMC perspective, a slightly lower but reproducible titer may be more valuable than a high titer that cannot be consistently reproduced.

For example, a process that repeatedly produces AAV at a moderate titer with controlled empty capsid levels may be more clinically and regulatory relevant than a process that occasionally produces very high titer but fluctuates widely in capsid quality.

An Illustrative Industry Scenario

Consider an AAV program that completes animal efficacy studies using a lot reported at 1 × 10¹³ vg/mL. The results appear strong, and the team begins preparing for IND-enabling activities.

Before submission, the sponsor commissions AUC testing and discovers that the lot contains a high proportion of empty capsids. This finding changes the interpretation of the preclinical material. Although the vector genome titer was accurate, the total capsid burden administered to animals may have been much higher than originally appreciated. The product may also contain fewer therapeutically relevant full particles than assumed.

The team now faces several CMC questions:

• Was the observed efficacy driven by the intended full capsid population?
• Was the safety profile influenced by a high total capsid load?
• Can the purification process be improved to enrich full capsids?
• Can the improved process reproduce comparable potency and safety?
• Is additional bridging or comparability work required?

This type of scenario illustrates why titer alone can be misleading. The problem is not that the titer method necessarily “lied.” The problem is that the team asked an incomplete question.

The better question is not simply: What is the vg/mL?

The better question is: What proportion of that titer represents reproducible, intact, therapeutically relevant AAV product?

Practical Guidance for AAV Developers

Discovery and Early Research Stage

At the early research stage, qPCR or ddPCR titer data may be acceptable for screening purposes. However, teams should avoid overinterpreting titer as proof of quality.

Recommended actions include:

• Requesting TEM or another orthogonal particle assessment when possible
• Recording whether the supplier provides total particle data or only vg/mL
• Designing dose-ranging studies with enough flexibility to account for later capsid-quality adjustments
• Preserving reference material for future comparability analysis

Pre-IND Stage

If an IND submission is expected within 12 months, AAV CMC work should begin early. Analytical characterization should not be delayed until the final GMP batch.

Recommended actions include:

• Establishing ddPCR or a well-justified qPCR method for vector genome titer
• Introducing AUC, SEC-MALS, or another orthogonal method for capsid characterization
• Evaluating genome integrity and packaged DNA species
• Assessing potency and its relationship to vector genome titer
• Generating multi-batch data to understand process variability
• Defining preliminary critical quality attributes and acceptance criteria

GMP Manufacturing Stage

At the GMP stage, empty capsid ratio should be considered for inclusion in the product specification or control strategy, depending on product risk and development phase. If it is treated as informational only, the sponsor should have a strong scientific justification.

Recommended actions include:

• Using qualified or validated analytical methods appropriate for the stage of development
• Establishing predefined acceptance criteria or alert/action limits
• Demonstrating batch-to-batch consistency
• Linking capsid quality to potency, safety, and dose rationale
• Maintaining raw data and method documentation suitable for regulatory review

Supplier Evaluation

A supplier’s statement that an AAV product has “low empty capsids” should be supported by data. Sponsors should request:

• Raw AUC or SEC-MALS data where applicable
• Method qualification or validation summary
• Representative electropherograms, sedimentation profiles, or chromatograms
• Batch history and comparability data
• Clear definitions of full, partial, and empty capsid reporting

A report that relies only on A260/A280 should not be considered a complete AAV capsid-quality package for IND-enabling development.

Frequently Asked Questions

Q1: qPCR and ddPCR give different AAV titers. Which one should we use?

Both qPCR and ddPCR are commonly used for AAV vector genome quantification. ddPCR has advantages because it provides absolute quantification and does not depend on a standard curve. It can improve reproducibility and reduce some sources of assay variability.

However, ddPCR is not automatically correct in all cases. Assay design, primer-probe location, genome structure, sample preparation, nuclease treatment, and reference material can all affect the result. If a program transitions from qPCR to ddPCR, the sponsor should perform bridging studies and explain any titer shift in the regulatory package.

Q2: Can a high empty capsid ratio be compensated by increasing dose?

This is generally not an appropriate strategy for clinical development. Increasing dose may increase immune activation risk, liver burden, and off-target safety concerns.

Dose escalation cannot substitute for adequate control of capsid quality. The better approach is to improve the production and purification process and establish a scientifically justified dose based on well-characterized material.

Q3: Can research-grade batch consistency data replace GMP batch data?

Research-grade data can support process understanding, but it generally cannot replace GMP-relevant release and characterization data. If resources are limited, sponsors may use engineering runs to support process development and risk assessment, followed by GMP batch data to support clinical use.

The final strategy should be discussed with regulatory authorities, particularly for rare disease programs, severe indications, accelerated development timelines, or products with limited manufacturing history.

Conclusion

For AAV development, vector genome titer remains an important measurement, but it should not be treated as the sole indicator of product quality. AAV products are complex biological systems, and their clinical performance depends on more than vg/mL.

The core CMC questions are:

• How much of the product is full, intact, and therapeutically relevant?
• How much empty or partial capsid material is present?
• How consistent is the process across batches?
• Are the analytical methods robust enough to support regulatory review?
• Is the control strategy aligned with product-specific risk?

A high AAV titer may look impressive, but batch consistency and capsid quality are what determine whether a product is truly ready for clinical development.

In modern AAV CMC, the most important question is no longer simply: How high is the titer?

It is: How much of that titer represents consistent, functional, and clinically meaningful AAV product?

References

1. Park S, Shin S, Lee H, Jang JH, Lee GM. Enhancing the production of adeno-associated virus (AAV)2 and AAV9 with high full capsid ratio in HEK293 cells through design-of-experiment optimization of triple plasmid ratio. Biotechnology Journal. 2024;19(3).
2. U.S. Food and Drug Administration. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs): Guidance for Industry.
3. European Medicines Agency. Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products.
4. European Medicines Agency. Reflection Paper on Quality, Non-clinical and Clinical Issues Related to the Development of Recombinant Adeno-Associated Viral Vectors.
5. Dark Horse Consulting Group. Proposed Draft Guidance for FDA Consideration: Testing of Adeno-Associated Viral (AAV) Vector-Based Human Gene Therapy Products for Empty Capsids During Product Manufacture.
6. Lock M, Alvira MR, Chen SJ, Wilson JM. Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Human Gene Therapy Methods. 2014;25(2):115–125.